Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in ESA-naive Lower-risk MDS (LENNON)
NCT05384691Phase 2Recruiting
- Sponsor
- Leipzig University
- Start
- Sep 2022
- Primary completion
- Jul 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of luspatercept in myelodysplastic syndrome (MDS), anemia, sponsored by Leipzig University. Started Sep 2022; status: recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)anemia
Beyond the preview
Go deeper on NCT05384691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384691.